HC Wainwright Issues Positive Estimate for AVXL Earnings

Anavex Life Sciences Corp. (NASDAQ:AVXL - Free Report) - Equities researchers at HC Wainwright raised their Q1 2025 earnings per share estimates for Anavex Life Sciences in a report released on Thursday, December 26th. HC Wainwright analyst R. Selvaraju now forecasts that the biotechnology company will post earnings per share of ($0.17) for the quarter, up from their prior estimate of ($0.19). HC Wainwright has a "Buy" rating and a $42.00 price target on the stock. The consensus estimate for Anavex Life Sciences' current full-year earnings is ($0.55) per share. HC Wainwright also issued estimates for Anavex Life Sciences' Q2 2025 earnings at ($0.18) EPS, Q3 2025 earnings at ($0.21) EPS and FY2025 earnings at ($0.73) EPS.

Separately, D. Boral Capital reaffirmed a "buy" rating and set a $46.00 price target on shares of Anavex Life Sciences in a report on Monday, December 23rd.

Anavex Life Sciences Price Performance

Shares of Anavex Life Sciences stock traded down $1.07 during trading on Monday, hitting $11.04. 2,786,842 shares of the stock were exchanged, compared to its average volume of 1,283,546. The stock has a market cap of $936.37 million, a price-to-earnings ratio of -22.08 and a beta of 0.73. The firm's 50-day moving average price is $8.29 and its 200 day moving average price is $6.46. Anavex Life Sciences has a 12-month low of $3.25 and a 12-month high of $14.44.

Anavex Life Sciences (NASDAQ:AVXL - Get Free Report) last announced its quarterly earnings data on Monday, December 23rd. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.17) by $0.03.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. Orion Capital Management LLC boosted its stake in Anavex Life Sciences by 666.7% in the third quarter. Orion Capital Management LLC now owns 11,500 shares of the biotechnology company's stock valued at $65,000 after acquiring an additional 10,000 shares in the last quarter. PVG Asset Management Corp acquired a new stake in shares of Anavex Life Sciences in the 3rd quarter valued at about $74,000. Atria Investments Inc purchased a new position in Anavex Life Sciences during the 3rd quarter worth approximately $76,000. BNP Paribas Financial Markets increased its position in Anavex Life Sciences by 97.0% during the third quarter. BNP Paribas Financial Markets now owns 15,074 shares of the biotechnology company's stock worth $86,000 after buying an additional 7,421 shares during the period. Finally, China Universal Asset Management Co. Ltd. lifted its stake in Anavex Life Sciences by 64.0% in the third quarter. China Universal Asset Management Co. Ltd. now owns 16,309 shares of the biotechnology company's stock valued at $93,000 after buying an additional 6,366 shares during the last quarter. 31.55% of the stock is owned by hedge funds and other institutional investors.

Anavex Life Sciences Company Profile

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.